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Abstract
Aims The study aims to systematically assess the diagnostic performance of cardiac magnetic resonance (CMR) and nuclear
scintigraphy (index tests) for the diagnosis and differentiation of subtypes of cardiac amyloidosis.
Methods and results MEDLINE and Embase electronic databases were searched for studies evaluating the diagnostic perfor-
mance of CMR or nuclear scintigraphy in detecting cardiac amyloidosis and subsequently in differentiating transthyretin am-
yloidosis (ATTR) from immunoglobulin light-chain (AL) amyloidosis. In this meta-analysis, histopathological examination of
tissue from endomyocardial biopsy (EMB) or extra-cardiac organs were reference standards. Pooled sensitivity, specificity, pos-
itive likelihood ratio, and negative likelihood ratio were calculated, and a random effects meta-analysis was used to estimate
diagnostic odds ratios. Methodological quality was assessed using a validated instrument. Of the 2947 studies identified, 27
met the criteria for inclusion. Sensitivity and specificity of CMR in diagnosing cardiac amyloidosis was 85.7% and 92.0% against
EMB reference and 78.9% and 93.9% with any organ histology reference. Corresponding sensitivity and specificity of nuclear
scintigraphy was 88.4% and 87.2% against EMB reference and 82.0% and 98.8% with histology from any organ. CMR was un-
able to reliably differentiate ATTR from AL amyloidosis (sensitivity 28.1–99.0% and specificity 11.0–60.0%). Sensitivity and
specificity of nuclear scintigraphy in the differentiation of ATTR from AL amyloidosis ranged from 90.9% to 91.5% and from
88.6% to 97.1%. Pooled negative likelihood ratio and positive likelihood ratio for scintigraphy in this setting were 0.1 and 8,
with EMB reference standard. Study quality assessed by QUADAS-2 was generally poor with evidence of bias.
Conclusions Cardiac magnetic resonance is a useful test for diagnosing cardiac amyloidosis but is not reliable in further clas-
sifying the disease. Nuclear scintigraphy offers strong diagnostic performance in both the detection of cardiac amyloidosis and
differentiating ATTR from AL amyloidosis. Our findings support the use of both imaging modalities in a non-invasive diagnostic
algorithm that also tests for the presence of monoclonal protein.
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Introduction
Amyloidosis is frequently misdiagnosed and delayed in its
recognition, in part due to a perception that it is rare and
difficult to diagnose.1 However, screening studies using non-
invasive imaging in selected populations2 have detected TTR
amyloid deposition in 13% of patients hospitalised for heart
failure with preserved ejection fraction3; 16% of patients un-
dergoing transcatheter aortic valve implantation for severe
aortic stenosis4; and 5% of patients with presumed hypertro-
phic cardiomyopathy.5 Taken together, these findings suggest
a significant underdiagnosis of transthyretin amyloidosis
(ATTR) across a range of heart disease phenotypes.
Immunoglobulin light-chain (AL) amyloidosis and ATTR
account for 90% of all systemic forms,6 and their timely
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differentiation is critical. Left untreated, AL amyloidosis
is associated with a very poor prognosis and < 1 year
median survival in the presence of cardiomyopathy7,8;
however, chemotherapy directed at the underlying plasma
cell dyscrasia can prolong median survival to beyond
3 years.9 Transthyretin amyloid cardiomyopathy (ATTR-
CM), caused by deposition of misfolded TTR protein in
the heart, progresses slower than AL but is also fatal.
Infiltration of the myocardium and conduction system
leads to heart failure and death,10 but in contrast to AL
amyloidosis, no disease-modifying treatments are currently
licensed for use in Europe. Observational studies in patients
with ATTR-CM suggest that median survival, in the absence
of any disease-modifying treatment, varies between 3
and 5 years.11–13 Tafamidis, a TTR stabiliser, is the only
medicine that has been evaluated in a completed Phase 3
trial in patients with ATTR-CM.14 The Transthyretin Amy-
loidosis Cardiomyopathy Clinical Trial (ATTR-ACT) showed a
reduction in the incidence all-cause mortality and
cardiovascular-related hospitalisations with tafamidis as
compared with placebo among patients with hereditary or
wild-type ATTR-CM.14 A further Phase 3 trial of a small-
interfering RNA therapeutic, revusiran, was terminated
early due to a mortality imbalance.15 Other small-
interfering RNAs, or the use of antisense oligonucleotides,
could offer alternative therapeutic approaches that remain
to be investigated in ATTR-CM.16
Contrast enhanced cardiac magnetic resonance (CMR) is
useful in establishing the aetiology of heart failure17 and
can be suggestive of specific causes of cardiomyopathy by
virtue of its ability to detect expansion of the myocardial
interstitium caused by inflammation, fibrosis, or extracellu-
lar deposition of amyloid proteins.18 CMR is thought to of-
fer a greater diagnostic value than echocardiography in
detecting cardiac amyloidosis19 but may be limited in its
ability to distinguish the two predominant subtypes. When
CMR is combined with nuclear scintigraphy and a compre-
hensive screen for monoclonal protein, the need for a tis-
sue diagnosis is obviated in the majority of patients with
suspected cardiac amyloidosis.
The diagnostic performance of CMR and nuclear
scintigraphy has been reported in individual studies and in
single-modality meta-analyses.20,21 However, the reference
histopathological tests have included a combination of car-
diac and extra-cardiac tissue samples, and the results of dif-
ferent techniques using the same imaging modality have
been pooled in analyses. The aim of this study was to con-
duct a comprehensive overview of the accuracy and preci-
sion of these modalities and to systematically assess the
diagnostic performance of CMR and nuclear scintigraphy
for the detection of cardiac amyloidosis and for the subse-
quent differentiation of ATTR from AL amyloidosis, with his-
topathology from the heart or other organs considered
separately as reference standards.
Methods
Search strategy and selection criteria
A systematic search of English-language literature in MEDLINE
and Embase databases was performed for relevant publications
from inception to 7 November 2018. Our prospective protocol
included Medical Subject Headings terms and keywords related
to a diagnosis of ATTR-CM and cardiac amyloidosis, the refer-
ence diagnostic test (endomyocardial or extra-cardiac biopsy),
and index imaging tests (CMR and nuclear scintigraphy). Details
of the search strategy are shown in the Supporting Information,
Appendix S1. We also searched the Cochrane Library for any ad-
ditional data published before November 2018. The database
search was supplemented by examining reference lists of in-
cluded studies and review articles.20–22
Our inclusion criteria specified studies evaluating the perfor-
mance of an index test for ATTR-CM or cardiac amyloidosis
against a reference test. Investigations considered as an appro-
priate reference test were histological confirmation in tissue
taken at endomyocardial biopsy (EMB) or from an extra-cardiac
organ.23 CMR and nuclear scintigraphy were selected as the in-
dex imaging investigations to be evaluated by virtue of their in-
clusion in a consensus diagnostic algorithm2; echocardiography
also features but was excluded from our analyses because of
the difficulty in pooling data across highly heterogenous tech-
niques and parameters measured. Only studies reporting on
≥5 patients with ATTR-CM or cardiac amyloidosis were consid-
ered. Finally, those that did not report data in a format that per-
mitted the calculation of sensitivity and specificity, and
therefore likelihood ratios, were excluded.
Data extraction and quality assessment
Two independent reviewers (J. B. and M. L.) examined the
electronic searches and extracted information on study char-
acteristics, quality, and test results. Discrepancies were
solved by a discussion between J. B. and M. L., or with P. E.
Information was obtained on year of publication, country of
origin, sample size, patient demographics, index test, and ref-
erence test. Methodological quality of included studies was
independently assessed using the QUADAS tool.24 This sys-
tematic review was conducted according to the protocol reg-
istered with PROSPERO (registration no. CRD42018118065)
and in accordance with PRISMA guidance.25
Statistical analysis
Positive likelihood ratio (PLR) and negative likelihood ratio
(NLR) were calculated for each study. The likelihood ratio ex-
presses the magnitude by which the probability of disease is
modified in a given patient by the outcome of an index test.
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A PLR of ≥10 and an NLR of ≤0.1 were considered to provide
convincing diagnostic evidence, whereas those between 5
and 10, and 0.1 and 0.2 give strong diagnostic evidence.26,27
In light of the importance of avoiding a misdiagnosis of
ATTR-CM in a patient with AL amyloidosis,2,28 a very high
specificity (≥95%) and high PLR (≥10) were considered the
most important performance measures for an index test in
the detection of ATTR amyloidosis. In contrast, the perfor-
mance of a test in an individual in whom cardiac amyloidosis
is suspected is best evaluated by the ability of a negative test
to rule out cardiac amyloidosis, and therefore, a high sensitiv-
ity (≥90%) and low NLR (≤0.1) are the most important mea-
sures. Those patients with a positive test result will require
additional investigations, including the reference tests used
as a benchmark in this meta-analysis in the case of AL amy-
loidosis. In the context of detecting cardiac amyloidosis, the
results of nuclear scintigraphy scans were considered as pos-
itive when reported as Grade ≥ 1 using the Perugini visual
score,29 and negative when 0. In contrast, when used for dif-
ferentiating ATTR from AL amyloidosis, positive nuclear scin-
tigraphy scans were defined as a Perugini Grade ≥ 2. These
thresholds were used based on a previous study pooling data
from 8 centres that showed fewer false negatives when de-
tecting cardiac amyloidosis and fewer false positives in diag-
nosing ATTR amyloidosis when using this approach.2
The pooled diagnostic odds ratio (OR) and 95% confidence
interval were estimated using a random effects model,30 with
an inverse variance method of weighting. The diagnostic OR
represents the odds of a test result being positive in an
individual with the disease compared with one without the
disease. We performed statistical tests of heterogeneity (I2)
for studies evaluating the performance of nuclear scintigra-
phy; however, the I2 statistic was not calculated across CMR
studies because of the variability in cardiac anatomy assessed.
Estimates of diagnostic ORs are shown in forest plots accord-
ing to predefined subgroups based on the reference test (EMB
vs. histology from any organ) and the diagnosis (ATTR amy-
loidosis vs. cardiac amyloidosis). For sensitivity analyses, we
planned to assess the effect of excluding studies using extra-
cardiac histopathology as the reference test and those with
poor methodological quality as assessed using QUADAS-2.
We did not assess publication bias, because no proven statis-
tical method exists for meta-analyses of diagnostic accuracy
studies.31 We used STATA version 12 for the analyses.
Results
Of the 2947 studies, we identified 27 meeting the inclusion
criteria, including data on 3493 patients (Figure 1). Twenty-
two studies evaluated the performance of CMR in diagnosing ei-
ther cardiac amyloidosis or ATTR amyloidosis,19,32–49 with a fur-
ther five studies assessing the diagnostic performance of
nuclear scintigraphy.2,50–53 Seventeen studies assessing the per-
formance of index tests in the diagnosis of cardiac amyloidosis
included patients with a range of cardiac conditions, whereas
9 out of 11 studies diagnosing ATTR amyloidosis included pa-
tients with ATTR or AL amyloidosis only. Among the four studies
using nuclear scintigraphy to differentiate ATTR from AL amy-
loidosis, three studies specified a monoclonal protein screen in
the methodology, the complete results of which were available
in only one study.2 Among 11 studies using EMB as the refer-
ence test, five obtained tissue samples from the right ventricle
and one involved biventricular EMB33–35,37,42,49; the remaining
studies did not report on EMB technique. One study reported
no complications following EMB in all subjects,34 whereas
others did not comment on the incidence of complications.
Detecting cardiac amyloidosis using cardiac
magnetic resonance or nuclear scintigraphy
Our pre-specified criteria for diagnostic evidence of cardiac am-
yloidosis were a high sensitivity (≥90%) and low NLR (≤0.1). Ta-
ble 1 shows the performance of Perugini Grade ≥ 1 nuclear
scintigraphy in detecting cardiac amyloidosis. Pooling data
Figure 1 Flow diagram of articles included in the systematic review. ATTR-CM, transthyretin amyloid cardiomyopathy; CA, cardiac amyloidosis.
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across all three tracers evaluated (99mTc-DPD, 99mTc-PYP, or
99mTc-HMDP), nuclear scintigraphy offered strong diagnostic ev-
idence of cardiac amyloidosis but did not fulfil our criteria for
convincing test performance against either EMB or any organ
histology reference standard. Using an EMB reference, both
99mTc-DPD and 99mTc-PYP showed strong diagnostic evidence,
with sensitivities of 89.0% and NLRs of 0.1.
Studies assessing the performance of CMR in detecting car-
diac amyloidosis used the distribution of late gadolinium en-
hancement (LGE), thresholds of native T1 values, or
extracellular volume as an index test (Supporting Information,
Appendix S2). Patients included in these studies were selected
either based on a clinical suspicion of cardiac amyloidosis (defi-
nition varied) or a known diagnosis of cardiac amyloidosis with a
control cohort. The confirmed diagnoses of patients included in
11 studies assessing the performance of LGE in varying distribu-
tions for the detection of cardiac amyloidosis are shown in the
Supporting Information, Appendix S3. After cardiac amyloidosis
(n = 253, 49%), the most common diagnoses were hypertensive
heart disease (n = 80, 15%), hypertrophic cardiomyopathy
(n = 31, 6%), lysosomal storage disease (n = 24, 5%), and non-
ischaemic dilated cardiomyopathy (n = 22, 4%).
Subendocardial LGE, assessed in patients with suspected car-
diac amyloidosis, was defined as globally distributed in the
subendocardium19 or in a distribution over the entire subendo-
cardial circumference,34–36 irrespective of extension into myo-
cardium. The pooled sensitivity of subendocardial LGE in
patients with suspected cardiac amyloidosis ranged from
78.9% with histology from any organ as the reference standard
to 85.7%with EMB (Table 1). NLRs for subendocardial LGE were
0.2 against both reference standard tests, falling just short of
our pre-specified markers of convincing performance. Atrial
LGE, also assessed in patients with suspected cardiac amyloid-
osis, was a less useful measure than subendocardial LGE, as
both pooled sensitivity (74.4%) and NLR (0.3) were poorer. Diag-
nostic ORs in CMR tests for the detection of cardiac amyloidosis
are shown in Figure 2. An individual with confirmed cardiac
amyloidosis on EMB was 69 times more likely to have subendo-
cardial LGE than an individual without cardiac amyloidosis. In
comparison, an individual with cardiac amyloidosis was 46 times
more likely to have a Perugini Grade of ≥1 nuclear scintigraphy
scan than those without cardiac amyloidosis.
Three studies included patients with known systemic
amyloidosis or a plasma cell dyscrasia only, and evaluated
the use of CMR for the purpose of identifying those with
cardiac involvement. Each study assessed the presence of
LGE in any distribution that was defined by presence in the
subendocardium, myocardium, or a patchy distribution in
two studies, and using a semi-automated technique in an-
other. The presence of LGE in any distribution in this setting
performed well against a reference standard of any organ his-
tology, with a pooled sensitivity of 93.0% and an NLR of <0.1
(Supporting Information, Appendix S2).
Three studies assessed native T1 values for the detection
of cardiac amyloidosis, with sensitivities ranging from 74.0%
to 84.2% and NLRs from <0.1 to 0.2. We were unable to pool
results across these studies due to the use of inconsistent T1
value thresholds. A single study reporting on extracellular vol-
ume measurements for diagnosing cardiac amyloidosis
against an EMB reference reported a sensitivity and NLR of
95.7% and < 0.1, respectively. A single study evaluated ven-
tricular LGE among patients with suspected cardiac amyloid-
osis, reporting good performance of LV LGE for its
identification (sensitivity of 94.1% and NLR of 0.1).
Differentiating transthyretin amyloidosis from
immunoglobulin light-chain amyloidosis using
cardiac magnetic resonance or nuclear
scintigraphy
Our pre-specified criteria for differentiating ATTR from AL amy-
loidosis were a specificity of ≥95% and PLR of ≥10 (Table 2). Nu-
clear scintigraphy with a Grade of ≥2 using any of 99mTc-DPD,
Table 1 Pooled diagnostic performance in detecting cardiac amyloidosis among patients with clinical suspicion
Parameter No. of patients Prevalence, n (%) Sensitivity (%) Specificity (%) PLR NLR
Grade 1/2/3 nuclear scintigraphy vs. EMB reference
99mTc-DPD ≥ 12 244 209 (85.6) 89.0 88.6 8 0.1
99mTc-PYP ≥ 12 109 100 (91.7) 89.0 77.8 4 0.1
99mTc-HMDP ≥ 12 21 18 (85.7) 77.8 100 3 0.2
Summary 374 327 (87.4) 88.4 87.2 7 0.1
Grade 1/2/3 nuclear scintigraphy vs. any organ histology
99mTc-DPD ≥ 12,53 991 559 (56.4) 81.9 98.8 71 0.2
99mTc-PYP ≥ 12 193 145 (75.1) 91.7 95.8 22 0.1
99mTc-HMDP ≥ 12,52 226 129 (57.1) 71.3 100 70 0.3
Summary 1410 833 (59.1) 82.0 98.8 68 0.2
Magnetic resonance vs. EMB reference
LGE subendocardium34,35,37 92 42 (45.7) 85.7 92.0 11 0.2
Magnetic resonance vs. any organ histology
LGE atria32,36 118 39 (33.0) 74.4 91.1 8 0.3
LGE subendocardium19,34,35,37 137 71 (51.8) 78.9 93.9 13 0.2
DT, deceleration time; EF, ejection fraction; LA, left atrial; LGE, late gadolinium enhancement; NLR, negative likelihood ratio; OR, odds ra-
tio; PLR, positive likelihood ratio.
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99mTc-PYP, or 99mTc-HMDP showed a PLR of >10 when evalu-
ated against a reference test of histology from any organ, and
specificity varied between 92.2% and 100%. The pooled PLR fell
to 8 among nuclear scintigraphy studies using histopathology
based on EMB alone. One study using Grade ≥ 2 nuclear scintig-
raphy with any one of the three tracers, combined with the ab-
sence ofmonoclonal protein in serum and urine immunofixation
electrophoresis and serumfree light-chain (sFLA) assay, reported
a specificity of 100%, both among 1217 patients with histology
from any organ and in 374 patients with EMB sourced histology
(Supporting Information, Appendix S4).2
Cardiacmagnetic resonance performed poorly in differentiat-
ing ATTR from AL amyloidosis; the predefined measures of in-
terest, specificity and PLR, were consistently lower across all
CMR index test parameters when comparedwith corresponding
measures for any nuclear scintigraphy test. Studies evaluating
the performance of CMR in this setting all used the presence
of LGE in varying regions of the heart as the index test (Figure
3). Left ventricular LGE was defined by presence in the LV myo-
cardium43,54 or any of the 17 LV segments.44 One study de-
scribed subendocardial LGE when there was global
subendocardial involvement but no transmural LGE;54 another
Figure 2 Pooled diagnostic odds ratios for detecting cardiac amyloidosis. LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; MR,
magnetic resonance; OR, odds ratio; RA, right ventricle; RV, right ventricle.
Table 2 Pooled diagnostic performance in differentiating ATTR-CM from AL amyloidosis
Index test No. of patients Prevalence, n (%) Sensitivity (%) Specificity (%) PLR NLR
Grade 2/3 nuclear scintigraphy vs. EMB reference
99mTc-DPD ≥ 22,51 262 170 (71.4) 94.7 90.2 10 <0.1
99mTc-PYP ≥ 22 109 85 (78.0) 87.1 79.2 4 0.2
99mTc-HMDP ≥ 22 21 14 (66.7) 78.6 100.0 6 0.2
Summary 392 269 (68.6) 91.5 88.6 8 0.1
Grade 2/3 nuclear scintigraphy vs. any organ histology
99mTc-DPD ≥ 22,50,51 917 379 (41.3) 94.5 97.2 34 <0.1
99mTc-PYP ≥ 22 199 122 (61.3) 83.6 92.2 11 0.2
99mTc-HMDP ≥ 22,52 205 89 (43.4) 85.4 100.0 100 0.1
Summary 1321 590 (44.7) 90.9 97.1 32 0.1
Magnetic resonance vs. any organ histology
LGE LA41,43 143 73 (51.0) 78.1 60.0 2 0.4
LGE RV41,45,54 535 377 (70.5) 93.9 34.2 1 0.2
LGE LV43,44,54 168 95 (56.5) 99.0 11.0 1 0.1
LGE subendocardium42,54 132 64 (48.5) 28.1 48.5 1 1.5
LGE transmural45,54 410 314 (76.6) 74.2 56.3 2 0.5
LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; MR, magnetic resonance; NLR, negative likelihood ratio; OR, odds
ratio; PLR, positive likelihood ratio; RA, right ventricle; RV, right ventricle.
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study defined it as global subendocardial LGE irrespective of
transmural involvement.42 Specificity of CMR in differentiating
ATTR from AL amyloidosis across all LGE distributions varied
from 11.0% to 60.0%, and PLRs varied from 1 to 2.
Quality assessment
Of the 28 studies meta-analysed, all scored high risk of bias in
the QUADAS-2 flow and timing domain (Supporting Informa-
tion, Appendix S5). This was because no single study reported
on blinding of index and reference test reporting, or the
timing of index and reference tests. Included studies
performed better in other domains with nine studies scored
as high risk of bias in patient selection, and all studies scoring
low risk in the other four domains of QAUDAS-2, including in-
dex test and reference test in both risk of bias and applicabil-
ity areas. Given that no included study scored a low risk of
bias across all domains, the planned subgroup analysis
excluding studies with high risk of bias was not performed.
Discussion
Cardiac magnetic resonance provides strong diagnostic evi-
dence for cardiac amyloidosis but is unable to effectively differ-
entiate its subtypes. Nuclear scintigraphy offers comparable
performance in diagnosing cardiac amyloidosis but can also re-
liably differentiate ATTR from AL amyloidosis affecting the
heart, when combined with a monoclonal protein screen. The
findings of this meta-analysis suggest that both modalities offer
sensitivity >85% for the diagnosis of cardiac amyloidosis
among patients with a clinical suspicion of the disease, with
low false positive rates. Based on the likelihood ratios reported
here, the absence of subendocardial LGE on CMR reduces the
pre-test probability of cardiac amyloidosis by around 30%,
and the absence of any cardiac uptake on nuclear scintigraphy
by 45%.55 It has been suggested that the poor sensitivity and
specificity of echocardiography in detecting cardiac amyloidosis
may contribute to the substantial misdiagnosis or delay in diag-
nosing it.2,56Our findings indicate that early use of nuclear scin-
tigraphy among patients with a high index of suspicion for
cardiac amyloidosis may offer an opportunity to accelerate di-
agnosis, prompting earlier referral for specialised assessment
and to direct further treatment.
The classical echocardiographic features suggesting cardiac
amyloidosis are concentric left ventricular wall thickening,
atrial septum thickening, and increased echogenicity of the
ventricular septum described as granular sparkling.23,57,58 In
practice, the disease is phenotypically heterogeneous, and
CMR evaluation in cardiac amyloidosis suggests that 42%
can have a remodelling pattern different from concentric in-
crease in LV wall thickness, including asymmetric and eccen-
tric remodelling.10,59 Furthermore, the sensitivity of granular
sparkling in diagnosing cardiac amyloidosis among patients
with a clinical suspicion has been reported as <50%.60,61 De-
spite being a valuable modality for investigating heart failure
and suggesting the possibility of cardiac amyloidosis, the abil-
ity of the classical echocardiographic features to make this
Figure 3 Pooled diagnostic odds ratios for Grade 2/3 scintigraphy and cardiac magnetic resonance in differentiating ATTR from AL cardiac amyloidosis.
LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; MR, magnetic resonance; OR, odds ratio; RA, right ventricle; RV, right ventricle.
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diagnosis has been limited by poor specificity and sensitivity.56
We did not perform a systematic assessment of
echocardiography in diagnosing cardiac amyloidosis due to
the significant heterogeneity in technique and parameters
measured. However, several novel echocardiogram parame-
ters in isolation or in combination have shown promising diag-
nostic performance (low NLR and high sensitivity) in individual
studies and merit further investigation.62–64
Nuclear scintigraphy demonstrated good diagnostic perfor-
mance both in the detection of cardiac amyloidosis using a
Perugini grade threshold of ≥1 and in the differentiation of its
subtypes using a threshold of ≥2. In this regard, nuclear scintig-
raphy offers some advantages over CMR in that it is able to de-
tect and differentiate cardiac amyloid; however, CMR yields
additional information on ventricular function and morphology,
and is able to detect a broader range of cardiomyopathies.18 As
such, in patients with a high index of suspicion for cardiac amy-
loidosis, early use of nuclear scintigraphy should be considered
as an alternative to CMR imaging. It is critical that any test used
to differentiate ATTR from AL amyloidosis has a near 100% spec-
ificity, so as not to miss AL amyloidosis requiring urgent chemo-
therapy. The seminal scintigraphy study included in this meta-
analysis, which pooled international data from 10 amyloidosis
centres, highlights the importance of performing a comprehen-
sive monoclonal protein screen (including serum and urine
immunofixation electrophoresis and serum free light chain
(sFLC) assay). When a negative monoclonal protein screen is
combined with Grade 2/3 scintigraphy, specificity improved
from 87% to 100% among patients with EMB-based histopathol-
ogy. Reporting of this ‘triple screen’ for monoclonal protein, in
combination with imaging, was incomplete in the remaining
three studies that assessed performance of scintigraphy in dif-
ferentiating ATTR from AL amyloidosis; therefore, we were un-
able to add additional data on the combined investigations in
our study.
In addition to the requirement for histological demonstration
and typing of amyloid among patients with a monoclonal pro-
tein, those with low cardiac uptake (Grade 1) on nuclear scintig-
raphy in the absence of a monoclonal protein also require
histological typing of amyloid. This is because of the low specific-
ity of any cardiac uptake (Grade 1, 2, or 3) for a diagnosis of
ATTR cardiac amyloid resulting mainly from low-grade uptake
in patients with cardiac AL.65 Results from specialist amyloid
centres suggest that as many as 19% of patients with ATTR am-
yloidosis will have a monoclonal protein and 9% will have low
cardiac uptake (Grade 1),2 demonstrating a clear ongoing need
for EMB in some patients. While extra-cardiac biopsy in clinically
suspected amyloidosis can yield a diagnosis in 50% to 80% of pa-
tients with AL amyloidosis,66 this falls to 35% in patients with
wild-type ATTR-CM.67 Furthermore, because of the potential
for false negative results for ATTR amyloidosis with a non-
invasive approach, a histological diagnosis from EMB should
be sought in any patient with suspected cardiac amyloidosis
where non-invasive diagnostic criteria are not met.2
In this analysis, we pooled the largest set of accuracy and
precision data so far, resulting in a four-fold increase in pa-
tient numbers with respect to CMR tests in detecting cardiac
amyloidosis.21 Furthermore, we were able to categorise histo-
logical reference tests according to whether an EMB was per-
formed or not. A previously published meta-analysis that
pooled performance of CMR across five studies reported sen-
sitivity of 85% and specificity of 92% for the presence of any
LGE, using a combination of reference tests including clinical
features and echocardiography.21 Our analyses provide addi-
tional information with respect to patient numbers, the use
of histological confirmation of diagnosis stratified by organ,
and finally on the distribution of LGE in the heart. We were
also able to provide a novel summary of the performance of
CMR in differentiating ATTR from AL amyloidosis. Our study
adds only a modest increase in patient numbers undergoing
scintigraphy due to the dominant weighting of one seminal
study evaluating this modality.2 The addition of data from four
relatively small studies to that provided in the seminal scintig-
raphy study reinforce the importance of combining this test
with the triple monoclonal protein screen in order to obtain
a specificity of 100% in differentiating ATTR from AL
amyloidosis.
Across studies using EMB and any organ histology as a ref-
erence test, we recorded consistent values in the important
measures of sensitivity and NLR for the detection of cardiac
amyloidosis with CMR. In contrast, the specificity and PLR
(important measures in differentiating ATTR from AL amyloid-
osis) fell when studies performing histology on extra-cardiac
biopsies were excluded from our analyses on nuclear scintig-
raphy. This discrepancy in performance of scintigraphy, when
comparing EMB or any organ histology reference standards
may relate to a reluctance to perform an EMB in elderly pa-
tients with multiple co-morbidities or in those with more ad-
vanced disease. It is possible that the likelihood of a positive
scan on nuclear scintigraphy may increase with age or sever-
ity of disease.68 Therefore, given patients with wild-type
ATTR-CM present at a more advanced age than those with
hereditary ATTR-CM, both older and more advanced patients
who are considered unfit to undergo EMB could be more
likely to have a positive scan.
Large historical case series suggest that rates of complica-
tions from EMB vary between 0% and 3%69–71; however, the
rate of major complications including ventricular perforation,
pericardial tamponade, and embolisation have clearly improved
over time. Contemporary series suggest that rates as low as 0%
and 0.3% may be achievable with high levels of experience for
left and right ventricular EMB, respectively.70 As demonstrated
in the included studies in this meta-analysis, right ventricular bi-
opsy is the more commonly used technique.72 The largest head-
to-head comparison in unselected patients who underwent
biventricular EMB found that 96% of left ventricular and 71%
of right ventricular showed diagnostic histopathological find-
ings; however, results were comparable when
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echocardiography was used to detect the most affected cham-
ber.70 In contrast, the role of CMR-guided targeting of areas
of LGE is more uncertain as there are conflicting reports on its
impact on diagnostic yield.73,74
There were many sources of potential heterogeneity
among included studies. While studies evaluating the use of
imaging modalities in diagnosing ATTR amyloidosis were con-
fined to a homogenous group of patients with either ATTR or
AL amyloidosis, CMR studies in the detection of cardiac amy-
loidosis included patients with a wide range of cardiac condi-
tions. All studies contributing data to our analyses reported
on clinically relevant populations undergoing CMR for
suspected cardiac amyloidosis; however, the underlying diag-
nosis of included patients will influence the presence and dis-
tribution of LGE. We excluded studies evaluating the
performance of tests in healthy individuals to ensure that
our analyses reflected clinical practice; however, it is possible
that the performance of tests will differ depending on the
non-diseased control population studied. Differences in the
imaging protocols between studies, and in the interpretation
of CMR, may also contribute to heterogeneity. Our findings
may be biased by the expert nature of centres contributing
data that may have imaging experience that is not widely ap-
plicable, particularly with respect to CMR. This bias could lead
to an overestimation of the diagnostic performance of index
tests. The width of confidence intervals in our pooled diagnos-
tic ORs was large and may relate to the limited number of
studies and between study heterogeneity that widens confi-
dence intervals in a random effects meta-analysis.
The findings of this meta-analysis provide strong evidence for
the early use of nuclear scintigraphy among patients with a
strong clinical suspicion of cardiac amyloidosis. We show that
nuclear scintigraphy performs consistently well in diagnosing
cardiac amyloidosis and differentiating its subtypes. Impor-
tantly, additional investigations that combine scintigraphy with
a triple screen for monoclonal protein are required to reach
the necessary near 100% specificity for a diagnosis of ATTR car-
diac amyloidosis. CMR also offers strong diagnostic evidence for
cardiac amyloidosis, and the sensitivity of subendocardial LGE is
superior compared with previous reports assessing echocardi-
ography for this purpose. CMR is not a good test for differenti-
ating ATTR-CM from AL amyloidosis. Ourfindings should prompt
health care services that interact with patients with suspected
cardiac amyloidosis to consider incorporating nuclear scintigra-
phy into their practice.
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